glp-1 receptor agonists hydration recommendations Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are medications that reduce food cravings, increase fullness, slow digestion, and can help control glp-1 benefits and risks hydration

In the SURPASS-2 trial, patients with obesity and T2D who received tirzeapatide (5 mg weekly) achieved greater HbA1c and body weight reductions than those receiving semaglutide (1 mg weekly) during the 40 week study ( With these points in mind, we undertook a broad assessment of published clinical data, curating the body weight loss (% from baseline), glycosylated hemoglobin levels (HbA1c), and nausea responses (% patients reporting) from the SUSTAIN 3, SUSTAIN 7, SCALE Diabetes, SURPASS 2, and STEP 2 trials ( Figures 1AC )

At the same time almost 40% of adults and a quarter of children with Medicaid have obesity and may benefit from having access to the drugs, according to KFF

Gut microbiota-derived metabolites, such as short-chain fatty acids (SCFAs), tryptophan metabolites, and immune stimulants, are likely mediators in this process [85]

A Personalized Weight Loss Journey At West Coast Plastic Surgery Center , we understand the transformative power of GLP-1 medications like Ozempic and Mounjaro

Coverage varies confirm benefits directly with your insurer

While those changes can support weight-management goals, they can also affect how much fluid people naturally consume